Advertisement

Topics

70% Repatha Cut? Amgen Counters With Own Study To Justify Price

20:54 EDT 23 Aug 2017 | Xconomy

Writing in the Journal of the American Medical Association, researchers at the University of California, San Francisco argued this week that the price of the cholesterol-fighting drug evolocumab (Repatha) should come down 70 percent, to $4,215 a year, to be cost-effective. But a separate study, published today in JAMA Oncology and funded by the drug’s […]

Original Article: 70% Repatha Cut? Amgen Counters With Own Study To Justify Price

NEXT ARTICLE

More From BioPortfolio on "70% Repatha Cut? Amgen Counters With Own Study To Justify Price"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cholesterol
Cholesterol is a waxy steroid metabolite found in the cell membranes and transported in the blood plasma. It is an important structural component of mammalian cell membranes, where it is establishes proper membrane permeability and fluidity. Cholesterol ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...